诺华Xiidra lifitegrast
Drug Class
Lymphocyte function-associated antigen-1 (LFA-1) antagonist淋巴细胞功能相关抗原-1 (LFA-1) 拮抗剂
Mechanism
Lifitegrast binds to lymphocyte function-associated antigen-1 (LFA-1) and blocks its interaction with intercellular adhesion molecule-1 (ICAM-1), inhibiting T-cell mediated ocular surface inflammation.立非司特结合淋巴细胞功能相关抗原-1 (LFA-1)，阻断其与细胞间粘附分子-1 (ICAM-1) 的相互作用，从而抑制 T 细胞介导的眼表炎症。
Approved Indication
Treatment of the signs and symptoms of dry eye disease (DED) in adults.用于治疗成人干眼症（DED）的症状和体征。
What This Means For Patients
Xiidra is a prescription ophthalmic solution designed to treat the signs and symptoms of dry eye disease. It works by blocking a specific protein interaction to reduce inflammation on the surface of the eye. It is available under the special-import drug policy in the Hainan Boao Lecheng pilot zone.Xiidra（立非司特）是一种用于治疗干眼症症状和体征的处方滴眼液。它通过阻断特定的蛋白质相互作用来减轻眼表炎症。该药已通过海南博鳌乐城特许通道引入。
Regulatory Approvals
- FDA — approved (2016) — label
Pivotal Clinical Evidence
- OPUS-2 — Tauber et al., Ophthalmology 2015 (NCT01635335) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.